Cervical cancer is a type of cancer that arises from the cervix. Almost all cervical cancers are either squamous cell carcinomas or adenocarcinomas. All women are at risk for cervical cancer. It occurs most often in women over age 30.
-
In 2020, American Cancer Society released an updated cervical cancer screening guideline calling for primary human papillomavirus (HPV) screening as the preferred strategy. Utility of HPV pr...
In this webinar, Jenny Meredith, Ph.D., HCLD(ABB), Clinical Microbiology Director at Prisma Health-Upstate joins forces with Sara Ezra, Molecular Supervisor at Pathology Consultants (subsidi...
ll purification by FACS has grown to become a mainstay of biomedical research since its invention in the early 1970s. FACS technology was initially designed and utilized to purify lymphoid p...
Date: January 19, 2023 Time: 11:00am (PST), 2:00pm (EST), 8:00pm (CET) There has been an evolution of organized HPV screening programs from the pap smear to liquid-based cytology, which has...
Date: November 9, 2021 Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CEST) An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organiz...
Date: August 31, 2022 Time: 12:00pm (PDT), 3:00pm (EDT), 9:00pm (CEST) Human papillomavirus (HPV) is responsible for more than 99% of cervical cancers. Most HPV infections are transient an...
Date: August 16, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) In this session, researchers, clinicians, and program implementers from four countries will address the disruption in co...
Date: June 29, 2022 Time: 12:00pm (PST), 2:00pm (EST), 8:00pm (CEST) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the ne...
La infección por el virus del papiloma humano (VPH) es el causante principal de cáncer de cuello uterino. Los tipos 16 y 18 del VPH son responsables...
Date: October 7, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Recently the FDA approved the BD Onclarity HPV assay as a test to identify HPV high-risk genotypes in addition to HPV 16 and 18 i.e.,...
DATE: August 18, 2020 TIME: 6:00am PDT, 9:00pm EDT Hundreds of HPV tests with different variants are commercially available globally, but many of these tests do not meet the performance char...
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...
DATE: May 8, 2019TIME: 12:00am PDT In 2017 the first national cervical screening programs using human papillomavirus (HPV-based) primary screening were implemented. As these progr...
The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with...
Cervical cancer is the 4th most common cancer worldwide with 528,000 new cases and 266,000 deaths every year. It is also the only cancer 100% preventable. It has been extensively proved, that...